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Abstract 
Objective. To assess the relationships between systemic IFN type I (IFN-I) and II (IFN-II) activity and 
disease manifestations in primary SS  (pSS). 
Methods. RT-PCR of multiple IFN-induced genes followed by  principal  component  analysis  of  whole 
blood RNA of 50 pSS patients was used to identify indicator genes of systemic IFN-I and IFN-II activities. 
Systemic IFN activation levels were analysed in two independent European cohorts (n = 86 and 55, re- 
spectively) and their relationships with clinical features were analysed. 
Results. Three groups could be stratified according to systemic IFN activity: IFN inactive (19-47%), IFN-I 
(53-81%) and IFN-I + II (35-55%). No patient had isolated IFN-II activation. IgG levels were highest in 
patients with IFN-I + II, followed by IFN-I and IFN inactive patients. The prevalence of anti-SSA and anti- 
SSB was higher among those with IFN activation. There was no difference in total-EULAR SS Disease 
Activity Index (ESSDAI) or ClinESSDAI between the three subject groups. For individual ESSDAI domains, 
only the biological domain scores differed between the three groups (higher among the IFN active groups). 
For patient reported outcomes, there were no differences in EULAR Sjo¨ gren’s syndrome patient reported 
index (ESSPRI), fatigue or dryness between groups, but pain scores were lower in the IFN active groups. 
Systemic IFN-I but not IFN-I + II activity appeared to be relatively stable over time. 
Conclusions. Systemic IFN activation is associated with higher activity only in the  ESSDAI biological 
domain but not in other domains or the total score. Our data raise the possibility that the ESSDAI bio-  
logical domain score may be a more sensitive endpoint for trials targeting either IFN pathway. 
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Introduction 
Primary SS (pSS) is characterized by lymphocytic infiltra- 
tions in salivary  and lachrymal  glands.  This  is accompa- 
nied by sicca symptoms and frequently also 
extraglandular manifestations [1-3]. Treatment is mainly 
symptomatic,  and  biologics  so  far  have  shown  limited 
efficacy. 
IFNs play a pivotal role in the pathogenesis of pSS. The 
presence of IFN-induced gene expression has been 
demonstrated in the salivary glands, peripheral blood 
mononuclear  cells,  isolated  monocytes  and  B  cells  of 
pSS patients [4-8]. This so-called IFN type I signature 
was associated with higher disease activity and higher 
levels of autoantibodies [9]. Recent findings also show 
activation of IFN type II-induced gene expression in saliv- 
ary glands of pSS patients [10, 11]. To our knowledge 
detailed analysis of modular IFN type I and II activation 
patterns in a large cohort of pSS patients has not been 
performed. 
Type I and II IFN bind to different receptors, but induce 
partially overlapping gene expression patterns. Therefore, 
it is difficult to determine which type of IFN triggers the 
IFN-induced gene expression pattern observed in pSS. 
However, understanding the relative contribution of IFN 
type I and II may deepen our knowledge in pSS patho- 
genesis and promote a stratified approach to therapeutic 
development. 
Systemic type I IFN activation has been extensively 
characterized in SLE. In clinical trials blocking  of  IFN 
type  I  had  limited  efficacy,  possibly  due  to unopposed 
type II IFN activation [12-14]. In SLE, Chiche et al. have 
reported three strongly upregulated IFN-annotated mod- 
ules (M1.2, M3.4 and M5.12) from peripheral blood tran- 
scriptomic data. Each of these modules has a distinct 
activation threshold [15]. The M1.2  transcriptional  
module was induced by IFNa, while both M1.2 and M3.4 
transcripts were upregulated by IFNb. M5.12 was poorly 
induced by IFNa and IFNb alone. Transcripts belonging to 
M3.4 and M5.12 were only fully induced by a combination 
of type I and II IFNs and displayed a more dynamic pattern 
when studied over time in SLE. Interestingly, M5.12 was 
mainly upregulated in SLE patients with high disease ac- 
tivity and correlated with renal flares. These data indicate 
that detailed modular analysis for pSS can contribute to 
the discovery of better biomarkers and development of 
stratified  therapeutic intervention. 
Fatigue is a major complaint in pSS patients [16-20] and 
is associated with a poor quality of life [21]. Patients 
receiving IFNa treatment for viral hepatitis can develop 
severe fatigue [22] and in rare cases also develop pSS- 
like symptoms [23-25]. Here we investigate a possible 
correlation between IFN activation and  fatigue. 
In this study, we performed a detailed analysis, using 
the IFN annotated modules described for SLE, in two 
large clinically well-characterized pSS cohorts—the 
United Kingdom Primary Sjo¨  gren’s Syndrome Registry 
(UKPSSR) and the Rotterdam (The Netherlands) cohort. 
Furthermore,   we   assessed   the   relationships between 
these IFN modules and fatigue as well as other clinical 
features. 
 
Methods 
Patient recruitment 
PSS patients and healthy controls (HCs) from the UK 
cohort were from the UKPSSR collected in 30 centres 
[26]. PSS patients and HC from the Rotterdam cohort 
were    recruited    at    the    Erasmus    Medical    Centre, 
Rotterdam, The Netherlands. All pSS  patients  fulfilled  
the 2002 American-European Consensus Group classifi- 
cation criteria [27]. Disease activity was assessed using 
EULAR Sjo¨ gren’s Syndrome Disease Activity Index 
(ESSDAI)  and  Clinical  ESSDAI  (ClinESSDAI)  [28,  29]. 
HCs did not suffer from autoimmune disease or use cor- 
ticosteroid. Characteristics of patients are summarized in 
supplementary Table S1, available at Rheumatology 
online. Written informed consent was obtained from all 
participants in the study, in compliance with the 
Declaration of Helsinki. The Medical Ethical Review 
Committee of the Erasmus MC and  North  West  
Research Ethics Committee approved this  study. 
 
Blood collection, measurement of laboratory 
parameters  and RT-PCR 
Blood was collected in clotting tubes for serum preparation 
and in PAXgene RNA tubes (PreAnalytix, Hombrechtikon, 
Switzerland) for whole blood RNA analysis. RNA isolation, 
cDNA preparation  and RT-PCR  were performed  according 
to the manufacturer’s protocol. See supplementary methods, 
available  at Rheumatology  online,  for extended protocols. 
 
Calculation of IFN score for each module 
To identify correlated groups of genes and reduce data 
complexity, the expression of IFN-inducible genes (from 
M1.2, M3.4 and M5.12) was added to a principle compo- 
nent  analysis.  Kaiser-Meyer-Olkin  measure of sampling 
adequacy were respectively 0.882, 0.907 and 0.888 for 
M1.2, M3.4 and M5.12. In order to assess the amount of 
variance explained by each factor, eigenvalues were 
extracted. 
The IFN score for each module was defined by the rela- 
tive expression of five indicator genes. For M1.2 these 
genes were IFI44, IFI44L, IFIT1, IFIT3 and MxA;  for  
M3.4, ZBP1, EIFAK2, IFIH1,  PARP9  and  GBP4;  and  
for  M5.12,  PSMB9,  NCOA7,  TAP1,  ISG20  and SP140. 
Mean and S.D.HC of each gene in the  HC  group  were 
used to standardize expression levels. IFN scores per 
subject represent the sum of these standardized scores, 
calculated as previously described [32, 33]. Patients were 
divided into groups that were positive or negative for  
M1.2, M3.4 or M5.12, using a threshold of mean HC + 2  
x S.D. HC. 
Assessment of fatigue and depressive symptoms 
In the UK cohort, fatigue was assessed using the profile of 
fatigue and discomfort-Sicca symptoms inventory (PROFAD- 
SSI), visual analogue scale (VAS) for fatigue and the EULAR 
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Sjo¨  gren’s syndrome patient reported index (ESSPRI) [28, 34, 
35]. In the Rotterdam cohort fatigue was assessed using the 
Dutch version of the multidimensional fatigue inventory (MFI) 
[36]. Depressive symptoms were assessed using the hospital 
anxiety and depression scale (HADS) for  the  UK  cohort  
and the Dutch-validated Center for Epidemiologic Studies 
Depression scale (CES-D) for the Rotterdam cohort [37,  38]. 
 
Statistics 
An independent t test was used to compare means and 
the Mann-Whitney U test was used to compare medians. 
Categorical data were compared using Fisher’s exact test 
and correlations were assessed using Spearman’s rho (rs). 
Multiple group comparisons were analysed using one-way 
analysis of variance (ANOVA) or the Kruskal-Wallis test. 
For   extended   statistics   see   supplementary  methods, 
available at Rheumatology online. 
 
 
Results 
Presence of IFN annotated modules in whole blood of 
pSS patients 
To select five indicator genes for each of the previously 
described IFN annotated modules (M1.2, M3.4 and M5.12) 
[15], 11-16 genes were selected using micro-array data of 
differentially expressed genes in monocytes of pSS patients 
(supplementary Table S2, available at Rheumatology online; 
unpublished results, Versnel et al.) [4]. Expression levels of 
these genes were assessed in 50 pSS patients and 38 HCs 
(Rotterdam cohort) using RT-PCR and added into a principle 
component analysis to identify correlated groups of genes in 
order  to reduce data  complexity. 
Five indicator genes for each module were selected and 
subsequently determined in a cohort of 86 pSS patients 
(UK cohort), followed  by  a  replication  cohort  of  55  
pSS patients (Rotterdam cohort). A flow chart summariz- 
ing this selection procedure is shown in supplementary 
Fig. S1, available at Rheumatology online. All IFN anno- 
tated modular scores were expressed significantly higher 
in pSS patients than in HCs (supplementary Fig. S2, 
available at Rheumatology online). Furthermore, the  
three IFN modules strongly  correlated  with  each other 
as depicted for the UK and Rotterdam cohorts combined 
(P < 0.001) (Fig. 1A). 
To study the modular expression over time, the modular 
IFN scores of 15 pSS patients of the Rotterdam cohort 
were determined at two different time points. The mean 
(S.D.) period between two time points was 1.8 (0.8) years. 
There were no significant differences in M1.2 and M3.4 
score between the two time points. In the M5.12 module 
there was a significant difference in score between the 
two time points (Fig. 1B). 
Of the M1.2 positive patients, 90-96% were also posi- 
tive for M3.4 and 66-67% were also positive for M5.12 
when both cohorts were combined. Only three patients 
were positive for M3.4 while negative for M1.2  and  
M5.12. There were no patients positive for M5.12 and 
negative for M1.2. 
In the UK cohort 81, 78, 55, 53 and 19% of the patients 
were positive for M1.2, M3.4, M5.12, all the modules and 
none of the modules, respectively (Fig. 1C). In the 
Rotterdam cohort this was respectively 53, 51, 35,  33  
and 47%. The percentage of patients positive for each 
module was lower in the Rotterdam cohort. Compared 
with the UK cohort, patients in the Rotterdam  cohort  
used more HCQ (supplementary Table S1, available at 
Rheumatology online). However, there were no differ- 
ences in IFN scores between patients treated or untreated 
with  HCQ  in  both  cohorts  (supplementary  Fig. S3A-F, 
available at Rheumatology online). 
 
Systemic upregulation of IFN-inducible genes is 
associated  with higher  prevalence  of autoantibodies 
While M1.2 and M3.4 modular gene expression largely 
overlapped in pSS patients, there was a subgroup that 
was additionally positive for M5.12. Therefore, pSS pa- 
tients were subgrouped into  patients  without  (negative 
for modular IFN activation), IFN type I- (positive for M1.2 
only) or IFN type I + II- (positive for M1.2 + M5.12) inducible 
gene expression. These three subgroups were subse- 
quently investigated for associations with clinical  data  
and functional tests. Functional tests were only available 
for the UK cohort. Patients with systemic IFN activation    
(I or I + II) were more often positive for anti-SSA and anti- 
SSB and had higher IgG levels compared with patients 
without  systemic  IFN  activation  in  both  cohorts  (UK 
cohort: Table 1, Fig. 2A, D and E; Rotterdam cohort: sup- 
plementary Table S3, supplementary Fig. S4A-E, avail- 
able at Rheumatology online). Furthermore, patients  with 
IFN type I + II-inducible gene expression showed signifi- 
cantly higher IgG and ESR levels and lower lymphocyte 
counts and haemoglobin levels compared with patients 
with  only  IFN  type  I-inducible  gene  expression  (UK 
cohort: Table 1, Fig. 2A-C). Schirmer’s test scores were 
significantly lower in IFN type I + II positive patients com- 
pared with patients without IFN activation (UK cohort: 
Table 1 and Fig. 2F). 
 
Systemic upregulation of IFN-inducible genes is 
associated with higher biological disease parameters 
but not clinical  ESSDAI 
To investigate differences in disease activity between pa- 
tients without, with IFN type I- and with IFN type I + II-in- 
ducible gene expression, the ESSDAI and its subdomains 
were compared between the different subgroups. The fre- 
quency of pSS patients positive for the biological domain 
was higher in patients with IFN activation compared with 
patients without IFN activation (UK cohort: Table 2; 
Rotterdam cohort: supplementary Table S4, available at 
Rheumatology online). In fact, activity in the biological 
domain is largely confined to the IFN active groups. The 
frequency of pSS patients positive for the haematological 
domain was higher in patients with IFN type I + II-inducible 
gene expression compared with patients without IFN-in- 
ducible gene expression or with only IFN type I-inducible 
gene   expression   in   the   UK   cohort.   There   were no 
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FIG. 1 Presence of IFN annotated modules in pSS patients from UK and Rotterdam cohort 
 
(A) Correlation between modular scores of the UK and Rotterdam cohorts combined (n = 141). (B) Modular scores over 
time in pSS patients (Rotterdam cohort) (n = 15). (C) Comparison positivity for modules M1.2, M3.4, M5.12, all modules or 
none of the modules between the UK cohort and the Rotterdam cohort. Dotted lines indicate positivity threshold for each 
score. For correlations, Spearman’s rho correlation test was used. Wilcoxon signed-rank test to compare dependent 
medians. Categorical data were compared using Fisher’s exact test. * Represents P value of < 0.05, ** represents P value 
of < 0.005, *** represents P value of < 0.0005. 
 
differences in total-ESSDAI or ClinESSDAI scores be- 
tween the different  subgroups. 
 
Systemic upregulation of IFNs is not associated with 
fatigue  or depression 
To investigate if there was a difference in patient-reported 
symptoms between patients without, with IFN type I- and 
with IFN type I + II-inducible gene expression, validated 
questionnaires for fatigue, depression and anxiety were 
analysed. Patients without IFN activation and those with 
IFN type I-inducible gene expression had higher pain 
scores, compared with patients with IFN type I + II-indu- 
cible gene expression (Table 3). There were no differences 
in fatigue, depression or anxiety between the pSS 
subgroups. 
 
 
Discussion 
In this study, we show the presence of systemic upregu- 
lation of IFN type I and IFN type I + II signatures in two 
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TABLE 1 Comparison of laboratory parameters in the UK cohort after stratification on IFN activation 
 
 
Laboratory parameters 
Anti-SSA, n (%) 11/16 (69) 20/22 (91) 44/47 (94) 0.026 
Anti-SSB, n (%) 5/15 (33) 15/21 (71) 32/46 (70) 0.007 
IgG, median (IQR), g/l 10.9 (9.1-13.4) 14.9 (12.4-17.9) 18.6 (14.1-26.2) <0.001 
IgA, mean (S.D.), g/l 2.3 (1.8) 2.8 (1.0) 3.4 (1.8) 0.077 
IgM, median (IQR), g/l 1.1 (0.9-1.7) 1.1 (0.8-1.5) 1.3 (1.0-1.7) 0.389 
C3, mean (S.D.), g/l 1.3 (0.2) 1.2 (0.3) 1.3 (0.2) 0.403 
C4, mean (S.D.), g/l 0.3 (0.04) 0.2 (0.06) 0.2 (0.1) 0.179 
Hb, mean (S.D.), g/l 13.2 (1.0) 13.4 (1.1) 12.4 (1.1) 0.001 9 
WCC, median (IQR), x10 6.5 (4.4-8.2) 5.7 (4.2-6.8) 5.7 (4.7-6.8) 0.217 
9 
Lymphocytes,  mean (S.D.), x10 2.0 (0.7) 1.8 (0.5) 1.6 (0.5) 0.007 9 
Neutrophils, median (IQR), x10 3.8 (2.3-5.1) 3.2 (2.3-4.4) 3.1 (2.7-4.3) 0.607 
9 
Plt, mean (S.D.), x10 305.8 (70.5) 276.5 (60.6) 264. (66.1) 0.087 
CRP, median (IQR), mg/l 3 (2.0-5.0) 5 (2.9-5.0) 5 (2.6-5.0) 0.567 
ESR, median (IQR), mm/h 14 (5.0-16.0) 19 (10.5-26.0) 31.5 (15.3-50.0) <0.001 
Functional tests     
Schirmer’s test, mean of both eyes, median  (IQR) 9.6 (4.0-22.5) 4.8 (1.0-13.6) 3.5 (0.5-8.0) 0.028 
Unstimulated saliva flow, median (IQR), ml/5 min 0.7 (0.1-2.9) 0.4 (0.0-1.1) 0.2 (0.0-1.0) 0.274 
Means or medians were compared using the one-way ANOVA or Kruskal-Wallis test. Categorical data were compared using 
Fisher’s exact test. CRP: C-reactive  protein; ESR: erythrocyte sedimentation rate; Neg: IFN negative; IFN I: IFN type I; IFN        
I + II: IFN type I and II; Ig: immunoglobulin; C: complement; Hb: haemoglobin; Plt: platelets; WCC: white cell count. 
 
 
FIG.  2  Relationship between modular IFN scores and laboratory and functional parameters 
 
 
IgG levels (A), lymphocyte counts (B), ESR (C), percentage positive for anti-SSA (D), percentage positive for anti-SSB 
(E) and Schirmer’s test (F) in IFN negative (n = 16), M1.2 positive (IFN type I inducible) (n = 22) or M5.12 positive (IFN type I 
+ II inducible) (n = 47) pSS patients. Kruskal-Wallis (A, C and F), one-way ANOVA (B) and Fisher’s exact test (D and E) 
were used to compare multiple groups. Asterisks represent P-values: *P <  0.05, **P <  0.005, ***P  <  0.0005. 
Neg (n = 16) IFN I (n = 22) IFN I + II (n = 47) P-value 
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TABLE 2 Comparison of the ESSDAI and its subdomains in the UK cohort after stratification on IFN activation 
 
 Neg (n = 16) IFN I (n = 22) IFN I + II (n = 47) P-value 
ESSDAI, median (IQR) 3 (0.5-5.0) 2.5 (0.0-5.0) 4 (0.0-8.0) 0.472 
ClinESSDAI, median (IQR) 4 (0.5-6.0) 2 (0.0-4.5) 4 (0.0-9.0) 0.929 
ESSDAI domain, n (%)     
Constitutional 4/16 (25) 4/22 (18) 10/47 (21)  
Lymphadenopathy 0/16 (0) 2/22 (9) 3/47 (6) 0.879 
Glandular 6/16 (38) 2/22 (9) 8/47 (17) 0.489 
Articular 7/16 (44) 6/22 (27) 17/47 (36) 0.167 
Cutaneous 1/16 (6) 0/22 (0) 2/47 (4) 0.664 
Pulmonary 1/16 (6) 1/22 (5) 7/47 (15) 0.660 
Renal 0/16 (0) 0/22 (0) 3/47 (6) 0.574 
Muscular 0/16 (0) 0/22 (0) 0/47 (0) 0.867 
PNS 0/16 (0) 0/22 (0) 2/47 (4) - 
CNS 0/16 (0) 0/22 (0) 0/47 (0) 0.437 
Haematological 0/16 (0) 0/22 (0) 7/47 (15) - 
Biological 0/16 (0) 8/22 (36) 23/47 (49) 0.046 
Medians were compared using Kruskal-Wallis test. Categorical data were compared using Fisher’s exact test. Neg: IFN 
negative; IFN I: IFN type I; IFN I + II: IFN type I and II; ESSDAI: EULAR Sjo¨ gren’s Syndrome Disease Activity Index. 
 
 
TABLE 3 Comparison of fatigue, depression, symptom profile and disease damage index after stratification on IFN 
activation 
 
 Neg IFN I IFN I + II P-value 
UK cohort 
SSDDI 
(n = 16) 
7.3 (5.0-7.3) 
(n = 22) 
7.3 (4.0-9.0) 
(n = 47) 
7.0 (3.0-8.7) 
 
0.791 
Fatigue VAS 85.0 (75.5-93.5) 77.0 (20.5-87.8) 76 (15.0-84.0) 0.149 
PROFAD-Physical 5.5 (4.5-6.0) 5.0 (2.6-6.0) 4.8 (1.8-5.5) 0.122 
PROFAD-Mental 4.0 (2.5-5.8) 4.5 (1.0-5.4) 3.5 (0.5-5.0) 0.531 
HADS anxiety 6.0 (4.5-7.0) 7.5 (5.0-11.0) 10.0 (5.0-12.0) 0.192 
HADS depression 7.0 (3.0-11.0) 8.0 (2.5-10.0) 5.0 (1.0-10.0) 0.322 
Total ESSPRI 7.0 (6.2-8.7) 6.7 (4.1-7.6) 5.8 (2.7-7.3) 0.047 
ESSPRI sub-domains     
Pain 7.0 (5.0-9.0) 6.0 (2.3-8.0) 3.5 (1.0-7.0) 0.003 
Fatigue 8.0 (7.0-9.0) 7.5 (3.5-9.0) 7.0 (2.0-8.0) 0.159 
Dryness 7.0 (5.5-8.0) 7.0 (4.0-8.5) 6.0 (3.0-8.0) 0.938 
Mental fatigue 7.0 (5.0-8.5) 5 (1.0-8.0) 3.0 (1.0-7.0) 0.058 
Rotterdam cohort     
MFI sub-domains 
General fatigue 
(n = 25) 
15.0 (12.0-17.8) 
(n = 11) 
16.0 (13.0-18.0) 
(n = 19) 
14 (2.75) 
 
0.793 
Physical fatigue 14.0 (12.0-16.0) 14.0 (10.0-15.0) 13.5 (9.0-20.0) 0.305 
Mental fatigue 12.0 (8.0-15.0) 11.0 (5.0-12.0) 10.0 (8.0-15.0) 0.322 
Reduced motivation 11.0 (8.0-14.0) 9.0 (5.0-13.0) 9.0 (5.9-11.0) 0.529 
Reduced activity 11.0 (7.0-13.0) 11.0 (8.0-16.0) 11.0 (7.0-13.0) 0.941 
CES-D 17.5 (8.0-23.5) 12.0 (8.0-20.0) 13.5 (10.0-20.0) 0.760 
Data are presented as median (IQR). Medians were compared using Kruskal-Wallis. SSDDI, Sjo¨  gren’s Syndrome Disease 
Damage Index; PROFAD, Profile  of  Fatigue  and  Discomfort;  HADS,  Hospital  Anxiety  and  Depression;  ESSPRI,  EULAR 
Sjo¨  gren’s Syndrome Patient Reported Index; CES-D, Center for Epidemiologic Studies Depression Scale;  MFI,  Multiple 
Fatigue Inventory. 
 
 
 
large clinically well-characterized European pSS cohorts, 
using five indicator genes of the previously described IFN 
annotated modules. IFN type I (M1.2) induced mainly by 
IFNa, was the most prevalent in both cohorts. IFN type 
 
I + II (M1.2 + M5.12), induced by IFNa, IFNb and IFNg, was 
present in "'"66% of the patients positive for IFN type I. 
Compared with patients without or with only IFN type I- 
inducible  gene  expression,  pSS  patients  with  IFN type 
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I + II-inducible gene expression were more often positive 
for the biological domain of the ESSDAI and had higher 
levels of IgG, higher ESR and lower lymphocyte counts in 
the UK cohort. In the Rotterdam cohort IgG levels of pa- 
tients with IFN type I + II were also higher compared with 
HCs and there was a trend towards lower lymphocyte 
counts. There were no differences in patient-reported fa- 
tigue or depression between patients with and without 
systemic  IFN activation. 
We have previously shown systemic IFN activation in 
peripheral blood monocytes in a subset of pSS patients 
[9]. This type I IFN signature correlated with higher anti- 
SSA/anti-SSB autoantibody frequencies and hypergam- 
maglobulinaemia. Comparison of these genes with the 
modules we tested in this study revealed that the IFN  
type I signature genes we used were all of the M1.2 
module and thus type I induced. Indeed all patients posi- 
tive for M1.2 were previously found to have a positive 
monocytic IFN signature [9]. 
Until now no detailed studies on the presence of a sys- 
temic IFN type II signature in pSS have been performed. A 
recent study in pSS has reported the presence of sys- 
temic type II IFN-induced gene expression, although  
using different genes from this study [39]. Similar percent- 
ages of types I and I + II positive patients were reported. 
However, 6.8% of the patients were exclusively positive 
for type II IFNs; in contrast, we did not find patients only 
positive for M5.12. This difference could be explained by 
the selection of GBP1 as a gene mainly induced by IFN 
type II. According to the modular analysis, which our  
study was based upon, this gene belongs to the M3.4 
module and therefore can also be induced by IFNb. 
The distribution of the modular IFN expression we 
detect in pSS is very similar to that earlier described for 
SLE. In pSS as well as SLE, M1.2 is the most prevalent 
module followed by M3.4 and M5.12 [15]. Additionally, 
similar to SLE, in pSS patients M5.12 was never upregu- 
lated without concomitant upregulation of M1.2 and M3.4. 
In SLE 87% of the patients showed upregulation of at 
least one of the modules. In our study 81% in the UK 
cohort was positive for at least one of the modules and    
in the Rotterdam cohort 53%. Longitudinal data indicated 
that in both diseases M5.12 is the module most suscep- 
tible to change over time, although our data are based 
upon a small sample number. A difference between SLE 
and pSS is that the M3.4 module largely overlaps with the 
M1.2 in pSS, while in SLE patients this was not observed 
[15]. The IFN modules correlated with auto-antibodies, 
anti-dsDNA titres in SLE and anti-SSA/anti-SSB in pSS. 
M5.12 in SLE correlated with SELENA-SLEDAI scores, 
flares and the cutaneous domain, and in pSS  this  
module weakly correlated with the pulmonary and renal 
domain of the ESSDAI (data not shown) in the UK cohort, 
but not the total-ESSDAI scores. A reason why we did not 
detect significant differences in total-ESSDAI or most 
ESSDAI domain scores in pSS could be because extra- 
glandular manifestations in pSS are less frequent than in 
SLE. Alternatively, IFN activity may be linked only to some 
but not all extraglandular  manifestations. 
Anti-inflammatory drugs can affect IFN signatures [40]. 
In this study, the frequency of patients positive for the 
modular IFN scores was lower in the Rotterdam cohort 
compared with the UK cohort. One possible explanation 
for this could be that patients in the Rotterdam cohort 
were treated more often with HCQ than patients in the   
UK cohort. We have shown before that patients treated 
with HCQ have lower IFN type I scores [40]. In addition, 
HCQ has been shown to impare IFNa production by plas- 
macytoid dendritic cells (pDCs) [41]. In this study, we also 
stratified patients based on HCQ use. Although there ap- 
peared to be a trend toward lower IFN type I (M1.2) scores 
among those taking HCQ, there were no significant differ- 
ences detected in any of the modular scores. However, 
this is a cross-sectional study with no data on pre-treat- 
ment IFN scores. Moreover, because of the contribution  
of other IFNs in pSS the overall effect of HCQ may not 
result in a significant difference in IFN score. Consistently, 
in SLE it was shown that HCQ treatment only lowered 
expression of MxA, with other interferon-inducible genes 
such as OAS1 and IFI27 being unaffected  [42]. 
Interestingly, there were no significant differences in 
total-ESSDAI or ClinESSDAI scores between patients with- 
out or with type I or type I + II IFN activation, except for the 
biological domain. This could have significant implications 
for selection of primary endpoints in clinical trials evaluating 
novel therapies. For instance, therapies targeting type I or II 
IFN may improve ESSDAI biological domain score, but 
have no impact on total-ESSDAI or ClinESSDAI scores. It 
is also of interest that systemic IFN activity is not asso- 
ciated with disease activity in other ESSDAI organ do- 
mains. One possible explanation is  that the sample size 
in this study did not have the power to detect such differ- 
ences. Another intriguing possibility is that mechanisms 
other than systemic IFN activation might be responsible 
for the clinical manifestations in these other organ domains. 
Recently, salivary gland analysis of pSS patients re- 
vealed a predominant type II activation pattern [11, 39]. 
Comparing these data with our results on systemic IFN 
activation we conclude that systemically IFN type I ex- 
pression dominated over IFN type II expression. This in- 
dicates that local and systemic IFN activation patterns 
within the same patient may differ. Future study of IFN 
activation patterns in paired samples from peripheral 
blood and salivary gland tissue of the  same  patient 
would be of interest and might help to define the role for 
systemic  IFN  activation  as  a  biomarker  for  pSS. 
Blocking systemic IFNa activation in SLE showed a re- 
duction of SELENA-SLEDAI scores in a small subset of 
patients [13, 14, 43]. Interestingly, post hoc analysis re- 
vealed a possible effect in patients with low baseline IFN 
activity. This might be due to a contribution of IFN type II 
or IFNb to the pathogenic process. A recent study target- 
ing the Interferon type I receptor (IFNAR) in SLE patients 
with moderate-to-severe disease showed encouraging 
clinical effectivity in patients with a high IFN signature at 
baseline, while patients with low IFN signatures did not 
respond differently compared with the placebo  group  
[44]. Our findings here in pSS and earlier finding in SLE 
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show distinct activation patterns (IFNa, IFNb and/or IFN 
type II) which all lead to upregulation of IFN-inducible 
genes. Stratification of patients based on their IFN activa- 
tion pattern will identify subgroups that are most likely to 
benefit from a specific targeted treatment. For instance, 
patients positive for M1.2 and M3.4 could benefit from 
blocking the IFNAR, while in patients additionally positive 
for M5.12, blocking the IFN type II pathway (as well as 
IFNAR blockade) might be necessary. 
In contrast to our hypothesis, patients with IFN activa- 
tion were not more fatigued than those without IFN signa- 
tures. This might be caused by the relatively low patient 
number or the subjective nature of fatigue. However, our 
data are in line with our previous study showing no cor- 
relation between IFN type I score and visual analogue 
scale fatigue score [45]. Additionally, we showed for the 
UK cohort lower levels of pro-inflammatory cytokines, 
among them IFN type II, in highly fatigued pSS patients 
[46]. These data indicate that fatigue is not directly related 
to activation of IFN-induced gene  expression. 
This study has several limitations. First is the study of 
gene expression levels in peripheral blood cells, instead of 
in a specific cell type. However, we previously investi- 
gated the IFN type I signature in monocytes of pSS pa- 
tients and identified the same set of signature genes as 
here in whole blood cells. Also, all patients positive for the 
monocytic IFN signature were also positive for M1.2 when 
whole blood cells were collected simultaneously. Another 
limitation is that the Rotterdam cohort is collected in an 
academic reference centre and therefore may have a dis- 
proportionately higher percentage of atypical pSS pa- 
tients while the UK cohort is a national biobank with 30 
recruitment centres. This may also explain the differences 
in the prevalence of renal complications between the two 
cohorts. 
Taken together, this study describes the prevalence of 
systemic (IFN types I and/or type II) activation in pSS. 
Stratification according to this activation pattern revealed 
differences in disease features. These data raise the pos- 
sibility that the biological-ESSDAI rather than total- 
ESSDAI score may be a more sensitive end point for  
trials targeting either type I or type II IFN pathway. 
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